… thyroid cancer. Here, we review the current genomic and the impacts of advances in therapies
to … In addition, from the view of the development of targeted therapy and immunotherapy, …

… current more personalized approach to patients with follicular cell-derived thyroid cancer …
recently was shown to have activity in anaplastic thyroid cancer (ATC). BRAF V600E inhibitors …

… Anaplastic thyroid cancer (ATC) is the rarest type of thyroid cancer but also the deadliest.
Its … However, the general accepted approach is total thyroidectomy because it has a higher …

… rare tumor, anaplastic thyroid carcinoma, is generally resistant to traditional antitumor
therapies. In recent years, targeted … Anaplastic thyroid carcinoma (ATC) is a rare and highly fatal …

… enhance or diminish response to anti-PD1 therapy, early reports suggest that the addition of
… a neoadjuvant approach [44]. Zafereo and colleagues have been testing this approach in a …

… Anaplastic thyroid cancer (ATC) is an infrequent highly aggressive thyroid malignancy
composed of undifferentiated thyroid … PET-CT changed the therapeutic approach in 8 out of 16 …

… In the event of locally advanced or metastatic disease, the … therapy and decompressive
cervical radiotherapy. Here we will review current knowledge on ATC and provide perspectives to …

… Anaplastic thyroid cancer (ATC) represents one of the most lethal human cancers and although
this tumor … Anaplastic thyroid cancer (ATC) is a highly aggressive malignancy with poor …

… -iodine refractory differentiated thyroid cancer and anaplastic thyroid cancer. In this review,
we … [67] This approach is supported by preclinical data showing that lenvatinib promotes a …

… Anaplastic thyroid cancer (ATC) is one of the deadliest human cancers and it is less than
2% of thyroid carcinomas (TCs). The standard treatment of ATC includes surgical debulking, …